Why Bavarian Nordic (CPSE:BAVA) Climbed After Its Latest Update

Bavarian Nordic (CPSE:BAVA) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to about DKK 5,700 million and completing a DKK 500 million share buyback program.

The latest results and guidance upgrade come after a strong short term rebound in Bavarian Nordic's share price, with a 7 day share price return of 15.45% and a 30 day share price return of 25.11%. However, the 1 year total shareholder return is down 8.7% and the 5 year total shareholder return is down 29.36%, which suggests that current momentum is building off a weaker long term base.

Compare Bavarian Nordic's rebound with a hand picked 610 high quality undiscovered gems that may also be flying under the radar after recent news and price moves.

Bavarian Nordic’s share price has moved sharply higher in a short span, while analyst targets and intrinsic value estimates still sit above the current level, at least on current numbers. Does that gap hint at further upside, or a market that is already catching up?

Most Popular Narrative: 20.2% Undervalued

The most followed valuation narrative currently puts Bavarian Nordic’s fair value at DKK 273.33 per share, compared with the latest close of DKK 218.20. That gap is built on detailed assumptions about future revenue, margins and the price investors might pay for earnings in a few years.

The company's recent revenue surge and margin strength are heavily anchored in exceptional short-term demand for travel health and public preparedness vaccines, which may be unsustainable as contract wins and outbreak-based orders normalize. This could lead to a flattening or decline in revenues and/or increased volatility in future earnings as pandemic and epidemic fears subside.

Read the complete narrative.

Want to understand why this narrative still reaches a higher fair value for Bavarian Nordic despite those headwinds? The core is how future earnings levels, margin compression and a higher future P/E are stitched together into one valuation story. The key inputs are already on the table. The real question is how they interact over time and what that implies for today’s DKK 218.20 price.

Result: Fair Value of DKK 273.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Bavarian Nordic’s story could change quickly if new competing vaccines pressure prices, or if government stockpiling slows and public preparedness contracts dry up faster than expected.

Find out about the key risks to this Bavarian Nordic narrative.

Next Steps

With mixed signals around Bavarian Nordic, it makes sense to move quickly, check the key data points yourself, and then weigh both the upside and the downside. To see the full picture of what the market currently views as potential positives and concerns, review the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Bavarian Nordic?

If Bavarian Nordic has caught your attention, do not stop there. Broader research across different types of stocks can sharpen your judgement and highlight opportunities you might otherwise miss.

Use the Simply Wall Street Screener to quickly surface focused sets of companies that match very different investment angles.

• Target potential value opportunities early by scanning a curated set of companies through the 272 high quality undervalued stocks.
• Prioritise resilience by reviewing a carefully filtered 295 resilient stocks with low risk scores that may help you balance bolder ideas like Bavarian Nordic.
• Zero in on quality balance sheets and fundamentals by working through a practical list of solid balance sheet and fundamentals (426 results) that could strengthen the core of your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com